Estado del arte en Biosimilares

SECIÓN 1- 2 marres 1 de junio

Prevención del efecto nocevo- Dr José A. Salas Sisado.

Revisión de la evidencia en vida Real Amgevita. Dr Erika Padilla.

SECIÓN 2- marres 22 de junio

-Biosimilares conceptos actuales Marco regulatorio – Dr. Jorge Murgas

– Adalimumab en AR Y EA ¿Cuándo es la mejor alternativa? Dr. Jesús Godoy

-Controversia en intercambiabilidad- Dr. Mauricio Abello.

Dr. José A. Salas Siado.│
Médico Internista Reumaótologo│
Barranquilla Colombia.}

Ingresar al Meeting en vivo:

Puedes realizar tus preguntas en los comentarios y serán respondidas por nuestros panelistas

No Comments

Cookie	Duración	Descripción
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.